Glaxosmithkline Intellectual Property Development Limited

Glaxo Group Limited

Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Pek Yoke Chong

Wieslaw Mieczyslaw Kazmierski

Hamilton D Dickson

Martha Alicia De La Rosa

Vicente Samano

Vincent Wing-Fai Tai

John Brad Shotwell

Andrew James Peat

Jason Gordon Weatherhead

Maosheng Duan

Eric Eugene Boros

Jennifer Poole Peckham

John G Catalano

Paul Richard Sebahar

Michael Youngman

James Benjamin Thompson

Felix Deanda, Jr

Neil Bifulco, Jr

Ed Williams McLean

Cecilia Suarez Koble

John Franklin Miller

Chrisopher Joseph Aquino

Brian Andrew Chauder

Angilique C Perkins

Dana Vanderwall

Hamilton Dickson

John F Miller

Martin R Leivers

Huichang Zhang

Martha De La Rosa

Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.

5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.

Modulators of indoleamine 2,3-dioxygenase

Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression. 

The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

Benzofuran compounds for the treatment of hepatitis C virus infections

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Chemical compounds

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

CCR5 antagonists as therapeutic agents

Growing community of inventors

Research Triangle Park, NC, United States of America

Pek Yoke Chong